Anthony C. Hooper - 11 Jun 2026 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Reporting relationship: Director
Issuer ticker: ONC
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:50:59 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Qing Nian, as Attorney-in-Fact

Key filing fact

Anthony C. Hooper filed Form 4 for BeOne Medicines Ltd. (ONC) on 15 Jun 2026.

Key facts

This page summarizes Anthony C. Hooper's Form 4 filing for BeOne Medicines Ltd. (ONC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 17:50.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001277244 Primary reporting owner

HOOPER ANTHONY C

Relationship: Director
Address: C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND
Signature: /s/ Qing Nian, as Attorney-in-Fact
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ONC transaction

Ordinary Shares

Award

Transaction value
Shares: +18,980
Change %: +29%
Price: $0.000000^*
Shares after: 83,720
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.